Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pediatric Surgery International
Published in: Pediatric Surgery International 9/2009

01-09-2009 | Original Article

Neuroblastoma: treatment outcome after incomplete resection of primary tumors

Authors: Suk-Bae Moon, Kwi-Won Park, Sung-Eun Jung, Woong-Jae Youn

Published in: Pediatric Surgery International | Issue 9/2009

Login to get access

Abstract

Purpose

For International Neuroblastoma Staging System (INSS) stages III or IV neuroblastoma (intermediate or high risk), complete excision of the primary tumor is not always feasible. Most current studies on the treatment outcome of these patients have reported on the complete excision status. The aim of this study is to review the treatment outcome after the incomplete resection.

Methods

The medical records of 37 patients that underwent incomplete resection between January 1986 and December 2005 were reviewed retrospectively. Incomplete resection was assessed by review of the operative notes and postoperative computerized tomography. Age, gender, tumor location, INSS stage, N-myc gene copy number, pre- and postoperative therapy, and treatment outcome were reviewed. The treatment outcome was evaluated according to the postoperative treatment protocol in the high-risk group.

Results

Intermediate-risk patients were treated with conventional chemotherapy, isotretinoin (ITT) and interleukin-2 (IL-2). High-risk patients were treated with peripheral blood stem cell transplantation (PBSCT), ITT, and IL-2 (N = 11). Before the introduction of PBSCT, the high-risk patients were also treated with the conventional chemotherapy (N = 19). Intermediate-risk patients (N = 5) currently have no evidence of disease (NED). For the high-risk patients (N = 32), 19 patients were treated with chemotherapy alone; 15 patients died of their disease while four patients currently have an NED status. Eight of 11 patients that underwent PBSCT are currently alive.

Conclusions

For intermediate risk, conventional chemotherapy appears to be acceptable treatment. However, for high-risk patients, every effort should be made to control residual disease including the use of myeloablative chemotherapy, differentiating agents and immune-modulating agents.
Literature
1.
Grosfeld JL (2006) Neuroblastoma. In: Grosfeld JL, O’Neill JA, Fonkalsrud EW, Coran AG (eds) Pediatric surgery, 6th edn. Mosby, St. Louis, pp 467–494
2.
Matthay KK, Perez C, Seeger RC et al (1998) Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children’s Cancer Group study. J Clin Oncol 16:1256–1264PubMed
3.
Adkins ES, Sawin R, Gerbing RB et al (2004) Efficacy of complete resection for high-risk neuroblastoma: a Children’s Cancer Group study. J Pediatr Surg 39:931–936PubMedCrossRef
4.
Michon J, De Bernardi B, Rubie H et al (2000) Surgery as the only treatment for INSS stage 2 neuroblastoma: risk factors predicting relapse. Med Pediatr Oncol 35:758
5.
La Quaglia MP, Kushner BH, Su W et al (2004) The impact of gross total resection on local control and survival in high-risk neuroblastoma. J Pediatr Surg 39:412–417PubMedCrossRef
6.
Stram DO, Matthay KK, O’Leary M et al (1996) Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children’s Cancer Group studies. J Clin Oncol 14:2417–2426PubMed
7.
8.
Reynolds CP, Matthay KK, Villablanca JG et al (2003) Retinoid therapy of high-risk neuroblastoma. Cancer Lett 197:185–192PubMedCrossRef
9.
Matthay KK, Villablanca JG, Seeger RC et al (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis retinoic acid. N Engl J Med 341:1165–1173PubMedCrossRef
10.
Ryu KH, Ahn HS, Koo HH et al (2003) Autologous stem cell transplantation for the treatment of neuroblastoma in Korea. J Korean Med Sci 18:242–247PubMed
11.
Lode HN, Xiang R, Dreier T et al (1998) Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91:1706–1715PubMed
12.
Vivancos P, Granena A (1999) Treatment with interleukin-2 (IL-2) and interferon after autologous bone marrow or peripheral blood stem cell transplantation in onco-hematological malignancies with a high risk of relapse. Bone Marrow Transplant 23:169–172PubMedCrossRef
13.
Ladenstein R, Phillip T, Lasset C et al (1998) Multivariate analysis of risk factors for stage 4 neuroblastoma over the age of one year treated with mega therapy and stem cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 16:953–965PubMed
14.
George RE, Li S, Medeiros-Nancarrow C, Neuberg D et al (2006) High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol 20:2891–2896CrossRef
15.
Matthay KK, Reynolds CP, Seeger RC et al (2009) Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study. J Clin Oncol 27:1007–1013PubMedCrossRef
16.
Handgretinger R, Greil J, Schürmann U et al (1997) Positive selection and transplantation of peripheral CD34+ progenitor cells: feasibility and purging efficacy in pediatric patients with neuroblastoma. J Hematother 6:235–242PubMed
17.
Lode HN, Handgretinger R, Schuermann U et al (1997) Detection of neuroblastoma cells in CD34+ selected peripheral stem cells using a combination of tyrosine hydroxylase nested RT-PCR and anti-ganglioside GD2 immunocytochemistry. Eur J Cancer 33:2024–2030PubMedCrossRef
18.
Häfer R, Voigt A, Gruhn B et al (1999) Neuroblastoma cells can express the hematopoietic progenitor cell antigen CD34 as detected at surface protein and mRNA level. J Neuroimmunol 96:201–206PubMedCrossRef
19.
Castel V, Tovar JA, Costa E et al (2002) The role of surgery in stage IV neuroblastoma. J Pediatr Surg 37:1574–1578PubMedCrossRef
Metadata
Title
Neuroblastoma: treatment outcome after incomplete resection of primary tumors
Authors
Suk-Bae Moon
Kwi-Won Park
Sung-Eun Jung
Woong-Jae Youn
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Pediatric Surgery International / Issue 9/2009
Print ISSN: 0179-0358
Electronic ISSN: 1437-9813
DOI
https://doi.org/10.1007/s00383-009-2417-8

Other articles of this Issue 9/2009

Pediatric Surgery International 9/2009 Go to the issue

Case Report

Congenital diaphragmatic hernia with a pure duplication of chromosome 1q: report of the first surviving case

Case Report

L1CAM mutation in association with X-linked hydrocephalus and Hirschsprung’s disease

Case Report

Anorectal malformation associated with a perineal protrusion of the rectal mucosa: case presentation

Original Article

Jaw and gum tumours in children

Original Article

Primary transanal Swenson pull-through operation for Hirschsprung’s disease

Original Article

Thoracoscopic bullectomy for primary spontaneous pneumothorax in pediatric patients